- Home
- CALC vs CLIK Comparison
CALC vs CLIK Comparison
Compare CALC & CLIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CALC
- CLIK
- Stock Information
- Founded
- CALC 2011
- CLIK 2017
- Country
- CALC United States
- CLIK Hong Kong
- Employees
- CALC N/A
- CLIK N/A
- Industry
- CALC Biotechnology: Pharmaceutical Preparations
- CLIK
- Sector
- CALC Health Care
- CLIK
- Exchange
- CALC Nasdaq
- CLIK NYSE
- Market Cap
- CALC 20.9M
- CLIK N/A
- IPO Year
- CALC N/A
- CLIK 2024
- Fundamental
- Price
- CALC $2.07
- CLIK $0.24
- Analyst Decision
- CALC Strong Buy
- CLIK
- Analyst Count
- CALC 3
- CLIK 0
- Target Price
- CALC $16.33
- CLIK N/A
- AVG Volume (30 Days)
- CALC 28.2K
- CLIK 6.0M
- Earning Date
- CALC 05-20-2025
- CLIK 02-14-2025
- Dividend Yield
- CALC N/A
- CLIK N/A
- EPS Growth
- CALC N/A
- CLIK N/A
- EPS
- CALC N/A
- CLIK 0.07
- Revenue
- CALC N/A
- CLIK $6,051,074.00
- Revenue This Year
- CALC N/A
- CLIK N/A
- Revenue Next Year
- CALC N/A
- CLIK N/A
- P/E Ratio
- CALC N/A
- CLIK $3.60
- Revenue Growth
- CALC N/A
- CLIK 36.12
- 52 Week Low
- CALC $1.43
- CLIK $0.16
- 52 Week High
- CALC $6.02
- CLIK $4.39
- Technical
- Relative Strength Index (RSI)
- CALC 69.21
- CLIK N/A
- Support Level
- CALC $1.52
- CLIK N/A
- Resistance Level
- CALC $2.15
- CLIK N/A
- Average True Range (ATR)
- CALC 0.13
- CLIK 0.00
- MACD
- CALC 0.08
- CLIK 0.00
- Stochastic Oscillator
- CALC 88.89
- CLIK 0.00
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.